Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Fangyuan Cao, Martijn R. H. Zwinderman, Frank J. Dekker
Molecules (2018) Vol. 23, Iss. 3, pp. 551-551
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors
Goverdhan Lanka, Darakhshan Begum, Suvankar Banerjee, et al.
Computers in Biology and Medicine (2023) Vol. 166, pp. 107481-107481
Closed Access | Times Cited: 58
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Rajat Sarkar, Suvankar Banerjee, Sk. Abdul Amin, et al.
European Journal of Medicinal Chemistry (2020) Vol. 192, pp. 112171-112171
Closed Access | Times Cited: 99
Strategies To Design Selective Histone Deacetylase Inhibitors
Jelena Melesina, Conrad V. Simoben, Lucas Praetorius, et al.
ChemMedChem (2021) Vol. 16, Iss. 9, pp. 1336-1359
Closed Access | Times Cited: 85
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
Joshua P. Smalley, India M. Baker, Wiktoria A. Pytel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5642-5659
Open Access | Times Cited: 56
The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
Ruyuan He, Bohao Liu, Boxin Geng, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 26
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
Antonio Curcio, Roberta Rocca, Stefano Alcaro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 620-620
Open Access | Times Cited: 14
Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties
Fabian B. Kraft, Jana Enns, Irina Honin, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107072-107072
Closed Access | Times Cited: 8
Epigenetics and meditation
Perla Kaliman
Current Opinion in Psychology (2018) Vol. 28, pp. 76-80
Closed Access | Times Cited: 67
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Ping Gong, Yuetong Wang, Yongkui Jing
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 7, pp. 1601-1601
Open Access | Times Cited: 56
Current trends in development of HDAC-based chemotherapeutics
Narges Cheshmazar, Maryam Hamzeh‐Mivehroud, Hojjatollah Nozad Charoudeh, et al.
Life Sciences (2022) Vol. 308, pp. 120946-120946
Closed Access | Times Cited: 34
HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Lili Li, Shumin Hao, Meiling Gao, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 5, pp. 657-673
Open Access | Times Cited: 21
Involvement of Epigenetic Mechanisms and Non-coding RNAs in Blood-Brain Barrier and Neurovascular Unit Injury and Recovery After Stroke
Svetlana M. Stamatovic, Chelsea M. Phillips, Gabriela Martínez-Revollar, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 53
Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors
Kunal Nepali, Ting-Yu Chang, Mei-Jung Lai, et al.
European Journal of Medicinal Chemistry (2020) Vol. 196, pp. 112291-112291
Closed Access | Times Cited: 42
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Yuxiang Luo, Huilin Li
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8828-8828
Open Access | Times Cited: 40
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
Hany S. Ibrahim, Mohamed Abdelsalam, Yanira Zeyn, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 369-369
Open Access | Times Cited: 40
The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury
Ning Li, Rui Xiong, Wang Bo, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 8
Open Access | Times Cited: 39
An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives
Ma Su, Xing-Yu Gong, Feng Liu
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 7, pp. 745-761
Closed Access | Times Cited: 33
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer
Sravani Pulya, Tarun Patel, Milan Paul, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114470-114470
Closed Access | Times Cited: 27
Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells
Fabian B. Kraft, Lukas Biermann, Linda Schäker‐Hübner, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 19, pp. 17796-17819
Closed Access | Times Cited: 5
Targeting HDAC Complexes in Asthma and COPD
Martijn R. H. Zwinderman, Sander de Weerd, Frank J. Dekker
Epigenomes (2019) Vol. 3, Iss. 3, pp. 19-19
Open Access | Times Cited: 42
The HDAC3 enzymatic activity regulates skeletal muscle fuel metabolism
Shiyang Song, Yefei Wen, H. N. Tong, et al.
Journal of Molecular Cell Biology (2018) Vol. 11, Iss. 2, pp. 133-143
Open Access | Times Cited: 39
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties
Viktoria Krieger, Alexandra Hamacher, Fangyuan Cao, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 24, pp. 11260-11279
Open Access | Times Cited: 39
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Linda Schäker‐Hübner, Reza Haschemi, Thomas Büch, et al.
ChemMedChem (2022) Vol. 17, Iss. 9
Open Access | Times Cited: 22
A TLR4/TRAF6-dependent signaling pathway mediates NCoR coactivator complex formation for inflammatory gene activation
Yohei Abe, Eric Kofman, Zhengyu Ouyang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 2
Open Access | Times Cited: 4
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents
Thabo Brighton Makgoba, Erika Kapp, Samuel Egieyeh, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 4, pp. 273-295
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top